High Speciality

At the vanguard of health care

With the desire of making health accessible and improving the well-being of the population, in 2005 we began with the development and production of highly specialized medications to treat chronic degenerative ailments.

We developed insulin glargine and human erythropoietin (biotechnological drugs), immunosuppressants such as tacrolimus and mycophenolate mofetil, as well as antiretrovirals for the human immunodeficiency virus (HIV), as well as other treatments for cancer and multiple sclerosis.

See our full portfolio

View catalog